Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Total Current Liabilities data on file, last reported at $72.0 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 4.75% year-over-year to $72.0 million in Q2 2026; TTM through May 2026 was $72.0 million, a 4.75% decrease from a year earlier, with the FY2025 full-year figure at $86.5 million, down 9.79% from the prior year.
• Total Current Liabilities for Q2 2026 stood at $72.0 million, down from $92.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NRIX reached as high as $95.9 million in Q4 2024 and fell as low as $61.5 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $78.4 million across 5 years, with a median of $78.2 million in 2024.
• Across the five-year window, Total Current Liabilities jumped 55.12% in 2022 and slipped 9.79% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $70.7 million in 2022, then climbed by 23.07% to $87.0 million in 2023, then rose by 10.23% to $95.9 million in 2024, then declined by 9.79% to $86.5 million in 2025, then dropped by 16.71% to $72.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $72.0 million in Q2 2026, $92.2 million in Q1 2026, and $86.5 million in Q4 2025.